Skip to main content


Figure 6 | Critical Care

Figure 6

From: Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study

Figure 6

Critical illness myopathy and insulin sensitivity. Normal (≥3 mV) and abnormal (< 3 mV) direct muscle stimulation compound muscle action potentials (dmCMAP), (a) insulin-like growth factor binding protein (IGFBP)-1 plasma levels, (b) IGFBP-3 plasma levels at median day (25th/75th percentile) 5 (3 to 7) and median day 8 (6 to 10,25). Patients with impaired muscle membrane excitability had significantly higher IGFBP-1 plasma levels but no significant differences of IGFBP-3 plasma levels at both measurement intervals.

Back to article page